Cypher Stent Outperforms Taxus in Diabetes Study

In patients with diabetes, Cordis’ Cypher sirolimus-eluting coronary stent outperformed Boston Scientific’s Taxus stent, according to clinical data in the Journal of the American College of Cardiology.

The study, conducted at five South Korean medical centers between 2005–2006, showed the Cypher stent had lower rates of reblockage within the stented area, additional interventional procedures and major adverse events such as heart attacks at nine months, Cordis said.

The multicenter, randomized clinical trial included 400 patients with diabetes and was divided evenly between each stent. The Cypher stent does not have an approved indication for use in patients with diabetes in the U.S.